作者
Douglass W Tucker, Christopher R Getchell, Eric T McCarthy, Anders W Ohman, Naoko Sasamoto, Shuyun Xu, Joo Yeon Ko, Mamta Gupta, Amy Shafrir, Jamie E Medina, Jonathan J Lee, Lauren A MacDonald, Ammara Malik, Kathleen T Hasselblatt, Wenjing Li, Hong Zhang, Samuel J Kaplan, George F Murphy, Michelle S Hirsch, Joyce F Liu, Ursula A Matulonis, Kathryn L Terry, Christine G Lian, Daniela M Dinulescu
发表日期
2018/3/15
期刊
Clinical Cancer Research
卷号
24
期号
6
页码范围
1389-1401
出版商
American Association for Cancer Research
简介
Purpose: A major challenge in platinum-based cancer therapy is the clinical management of chemoresistant tumors, which have a largely unknown pathogenesis at the level of epigenetic regulation.
Experimental Design: We evaluated the potential of using global loss of 5-hydroxymethylcytosine (5-hmC) levels as a novel diagnostic and prognostic epigenetic marker to better assess platinum-based chemotherapy response and clinical outcome in high-grade serous tumors (HGSOC), the most common and deadliest subtype of ovarian cancer. Furthermore, we identified a targetable pathway to reverse these epigenetic changes, both genetically and pharmacologically.
Results: This study shows that decreased 5-hmC levels are an epigenetic hallmark for malignancy and tumor progression in HGSOC. In addition, global 5-hmC loss is associated with a decreased response to platinum …
学术搜索中的文章
DW Tucker, CR Getchell, ET McCarthy, AW Ohman… - Clinical Cancer Research, 2018